ea0063p358 | Thyroid 1 | ECE2019
Daniel Sara
, Lommers Emilie
, Hansen Isabelle
, Dive Dominique
, Geenen Vincent
, Beckers Albert
, Valdes-Socin Hernan
Introduction: Alemtuzumab is a humanized monoclonal antibody against CD52, located on the surface of the lymphocytes, used in the treatment of relapsing-remitting multiple sclerosis (RRMS), that can induce novel secondary autoimmune diseases. Autoimmunity may be related to the pattern of T- and B-cell depletion and repopulation following Alemtuzumab treatment. The most frequently reported autoimmune disorders observed with alemtuzumab involve the thyroid gland in up to a third...